Literature DB >> 25675143

Ferret and pig models of cystic fibrosis: prospects and promise for gene therapy.

Ziying Yan1, Zoe A Stewart, Patrick L Sinn, John C Olsen, Jim Hu, Paul B McCray, John F Engelhardt.   

Abstract

Large animal models of genetic diseases are rapidly becoming integral to biomedical research as technologies to manipulate the mammalian genome improve. The creation of cystic fibrosis (CF) ferrets and pigs is an example of such progress in animal modeling, with the disease phenotypes in the ferret and pig models more reflective of human CF disease than mouse models. The ferret and pig CF models also provide unique opportunities to develop and assess the effectiveness of gene and cell therapies to treat affected organs. In this review, we examine the organ disease phenotypes in these new CF models and the opportunities to test gene therapies at various stages of disease progression in affected organs. We then discuss the progress in developing recombinant replication-defective adenoviral, adeno-associated viral, and lentiviral vectors to target genes to the lung and pancreas in ferrets and pigs, the two most affected organs in CF. Through this review, we hope to convey the potential of these new animal models for developing CF gene and cell therapies.

Entities:  

Mesh:

Year:  2015        PMID: 25675143      PMCID: PMC4367511          DOI: 10.1089/humc.2014.154

Source DB:  PubMed          Journal:  Hum Gene Ther Clin Dev        ISSN: 2324-8637            Impact factor:   5.032


  143 in total

Review 1.  Immunological hurdles to lung gene therapy.

Authors:  S Ferrari; U Griesenbach; D M Geddes; E Alton
Journal:  Clin Exp Immunol       Date:  2003-04       Impact factor: 4.330

2.  Quantitative analysis of the packaging capacity of recombinant adeno-associated virus.

Authors:  J Y Dong; P D Fan; R A Frizzell
Journal:  Hum Gene Ther       Date:  1996-11-10       Impact factor: 5.695

3.  Pancreatic damage in fetal and newborn cystic fibrosis pigs involves the activation of inflammatory and remodeling pathways.

Authors:  Maisam Abu-El-Haija; Shyam Ramachandran; David K Meyerholz; Marwa Abu-El-Haija; Michelle Griffin; Radhamma L Giriyappa; David A Stoltz; Michael J Welsh; Paul B McCray; Aliye Uc
Journal:  Am J Pathol       Date:  2012-06-08       Impact factor: 4.307

Review 4.  Chloride channels and cystic fibrosis of the pancreas.

Authors:  M A Gray; J P Winpenny; B Verdon; H McAlroy; B E Argent
Journal:  Biosci Rep       Date:  1995-12       Impact factor: 3.840

5.  Aerosol administration of a recombinant adenovirus expressing CFTR to cystic fibrosis patients: a phase I clinical trial.

Authors:  G Bellon; L Michel-Calemard; D Thouvenot; V Jagneaux; F Poitevin; C Malcus; N Accart; M P Layani; M Aymard; H Bernon; J Bienvenu; M Courtney; G Döring; B Gilly; R Gilly; D Lamy; H Levrey; Y Morel; C Paulin; F Perraud; L Rodillon; C Sené; S So; F Touraine-Moulin; A Pavirani
Journal:  Hum Gene Ther       Date:  1997-01-01       Impact factor: 5.695

6.  A novel chimeric adenoassociated virus 2/human bocavirus 1 parvovirus vector efficiently transduces human airway epithelia.

Authors:  Ziying Yan; Nicholas W Keiser; Yi Song; Xuefeng Deng; Fang Cheng; Jianming Qiu; John F Engelhardt
Journal:  Mol Ther       Date:  2013-07-30       Impact factor: 11.454

7.  Identification of the cystic fibrosis gene: chromosome walking and jumping.

Authors:  J M Rommens; M C Iannuzzi; B Kerem; M L Drumm; G Melmer; M Dean; R Rozmahel; J L Cole; D Kennedy; N Hidaka
Journal:  Science       Date:  1989-09-08       Impact factor: 47.728

8.  Repeated aerosolized AAV-CFTR for treatment of cystic fibrosis: a randomized placebo-controlled phase 2B trial.

Authors:  Richard B Moss; Carlos Milla; John Colombo; Frank Accurso; Pamela L Zeitlin; John P Clancy; L Terry Spencer; Joseph Pilewski; David A Waltz; Henry L Dorkin; Thomas Ferkol; Mark Pian; Bonnie Ramsey; Barrie J Carter; Dana B Martin; Alison E Heald
Journal:  Hum Gene Ther       Date:  2007-08       Impact factor: 5.695

9.  Nacystelyn enhances adenoviral vector-mediated gene delivery to mouse airways.

Authors:  R Kushwah; J R Oliver; H Cao; J Hu
Journal:  Gene Ther       Date:  2007-05-24       Impact factor: 5.250

10.  Second-strand genome conversion of adeno-associated virus type 2 (AAV-2) and AAV-5 is not rate limiting following apical infection of polarized human airway epithelia.

Authors:  Wei Ding; Ziying Yan; Roman Zak; Milene Saavedra; David M Rodman; John F Engelhardt
Journal:  J Virol       Date:  2003-07       Impact factor: 5.103

View more
  31 in total

Review 1.  The Enigmatic Gut in Cystic Fibrosis: Linking Inflammation, Dysbiosis, and the Increased Risk of Malignancy.

Authors:  Millie Garg; Chee Y Ooi
Journal:  Curr Gastroenterol Rep       Date:  2017-02

Review 2.  Inflammation: A Double-Edged Sword in the Response to Pseudomonas aeruginosa Infection.

Authors:  Christina K Lin; Barbara I Kazmierczak
Journal:  J Innate Immun       Date:  2017-02-22       Impact factor: 7.349

3.  Viral Vectors, Animal Models, and Cellular Targets for Gene Therapy of Cystic Fibrosis Lung Disease.

Authors:  Yinghua Tang; Ziying Yan; John F Engelhardt
Journal:  Hum Gene Ther       Date:  2020-04-15       Impact factor: 5.695

Review 4.  Modulating Innate and Adaptive Immunity by (R)-Roscovitine: Potential Therapeutic Opportunity in Cystic Fibrosis.

Authors:  Laurent Meijer; Deborah J Nelson; Vladimir Riazanski; Aida G Gabdoulkhakova; Geneviève Hery-Arnaud; Rozenn Le Berre; Nadège Loaëc; Nassima Oumata; Hervé Galons; Emmanuel Nowak; Laetitia Gueganton; Guillaume Dorothée; Michaela Prochazkova; Bradford Hall; Ashok B Kulkarni; Robert D Gray; Adriano G Rossi; Véronique Witko-Sarsat; Caroline Norez; Frédéric Becq; Denis Ravel; Dominique Mottier; Gilles Rault
Journal:  J Innate Immun       Date:  2016-03-18       Impact factor: 7.349

Review 5.  Impact of gene editing on the study of cystic fibrosis.

Authors:  Patrick T Harrison; David J Sanz; Jennifer A Hollywood
Journal:  Hum Genet       Date:  2016-06-21       Impact factor: 4.132

6.  Human Bocavirus Type-1 Capsid Facilitates the Transduction of Ferret Airways by Adeno-Associated Virus Genomes.

Authors:  Ziying Yan; Zehua Feng; Xingshen Sun; Yulong Zhang; Wei Zou; Zekun Wang; Chandler Jensen-Cody; Bo Liang; Soo-Yeun Park; Jianming Qiu; John F Engelhardt
Journal:  Hum Gene Ther       Date:  2017-05-10       Impact factor: 5.695

Review 7.  Innovative Therapies for Cystic Fibrosis: The Road from Treatment to Cure.

Authors:  Giulio Cabrini
Journal:  Mol Diagn Ther       Date:  2019-04       Impact factor: 4.074

8.  Reconstituting Mouse Lungs with Conditionally Reprogrammed Human Bronchial Epithelial Cells.

Authors:  Ryan LaRanger; Jennifer R Peters-Hall; Melissa Coquelin; Busola R Alabi; Christopher T Chen; Woodring E Wright; Jerry W Shay
Journal:  Tissue Eng Part A       Date:  2017-09-25       Impact factor: 3.845

Review 9.  Animal models for cystic fibrosis liver disease (CFLD).

Authors:  Romina Fiorotto; Mariangela Amenduni; Valeria Mariotti; Massimiliano Cadamuro; Luca Fabris; Carlo Spirli; Mario Strazzabosco
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2018-07-30       Impact factor: 5.187

Review 10.  Barriers to inhaled gene therapy of obstructive lung diseases: A review.

Authors:  Namho Kim; Gregg A Duncan; Justin Hanes; Jung Soo Suk
Journal:  J Control Release       Date:  2016-05-16       Impact factor: 9.776

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.